Approval in one of the world’s most stringent regulatory jurisdictions and important crop protection markets provides important regulatory precedent for Biotalys’ AGROBODY® biocontrols Ghent, BELGIUM, Sept. 02, 2026 (GLOBE NEWSWIRE) —             Press Release Biotalys (Euronext Brussels: BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announced that the California Department of Pesticide Regulation (CDPR) has granted state registration for EVOCA, the company’s first protein-based biofungicide. The approval follows the successful completion of the public consultation process earlier in July and confirms that EVOCA has successfully met the state’s stringent regulatory requirements for human health, environmental safety and product...

Regulated Information Nyrstar NV reviews aspects of its governance framework 2 September 2026 at 07.00 CEST Nyrstar NV (the “Company”) today announces that the Board has reviewed certain aspects of its governance framework. In light of the evolution of the Board’s composition and the recent developments in respect of the ongoing litigation and investigation, the Board has decided to establish an ad hoc advisory committee for the oversight of the Company’s material litigation and investigations (the “Litigation Committee”). The Committee will act in an advisory capacity to the Board and replaces the Special Committee for the procedure on the merits, established in 2024. It will provide focused review and advice to the Board across the Company’s material litigation matters. The Litigation Committee shall consist, at present,...

Louvain-la-Neuve, Belgium, 2 September 2026, 7 a.m.  – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its participation in PFAROS, a new European research and innovation initiative launched to address environmental emissions and exposure concerns related to per- and polyfluoroalkyl substances (PFAS) in the pharmaceutical and medical sectors. As part of the project, IBA will co-lead the work on end-of-life and waste-management technologies, bringing its electron beam and Rhodotron® expertise to the assessment of PFAS destruction solutions. A new European research and innovation initiative, PFAROS, has officially been launched and brings together a large consortium of 91 European and international partners from industry, academia, healthcare, regulatory bodies, and civil...

PERTH, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) is pleased to advise that it has released an update on exploration drilling completed at the Patterson Lake South (PLS) Project in Saskatchewan, Canada. The announcement is available on the Company’s website (https://www.paladinenergy.com/investors/asx-announcements/). This announcement has been authorised for release by the Board of Directors of Paladin Energy Ltd.Contacts  Investor RelationsPaula RaffoT: +61 8 9423 8100E: paula.raffo@paladinenergy.com.au MediaAnthony HasluckT: +61 438 522 194E: anthony.hasluck@paladinenergy.com.au   About Paladin Paladin Energy Ltd (ASX:PDN TSX: PDN OTCQX:PALAF) is a globally significant independent uranium producer with a 75% ownership of the world-class...

PERTH, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it will host its Investor Day in Sydney today and will webcast the event live commencing at 2:00pm AEST. The Investor Day will provide shareholders, investors and analysts with an update on Paladin’s strategy, operational performance and growth outlook. Following the transition of Langer Heinrich Mine (LHM) to full mining operations, the Investor Day will provide a deeper understanding of the quality, scale and strategic importance of the Patterson Lake South (PLS) Project. The program will highlight the progress made in de-risking the PLS Project, the pathway towards development, and its potential to create significant long-term value for shareholders. The Investor Day will also...

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) (“Skyworks”), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, today announced that it has extended the expiration date of its previously announced offers to holders of Qorvo Notes (as defined herein) to exchange (the “Exchange Offers”) any and all outstanding 4.375% Senior Notes due 2029 (the “2029 Qorvo Notes”) and any and all outstanding 3.375% Senior Notes due 2031 (the “2031 Qorvo Notes” and, together with the 2029 Qorvo Notes, the “Qorvo Notes”) issued by Qorvo, Inc. (“Qorvo”) as set forth in the table below for (1) with respect to the 2029 Qorvo Notes, up to $850,000,000 aggregate principal amount of new 4.375% Senior Notes due 2029 (the “New 2029 Skyworks...

In-house Drone Battery Production Capacity to Double by Mid-2027 FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) — Enovix Corporation (Nasdaq: ENVX) (“Enovix”), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, highlighted that its drone and defense battery portfolio manufactured in South Korea is compliant with the Trade Agreements Act (TAA), expanding the company’s ability to serve U.S. government defense programs. Enovix is doubling its in-house drone battery production capacity in South Korea by mid-2027 to support growing demand from the U.S. and allied government customers. “Secure access to high-performance batteries is increasingly critical to the national security of the United States and its allies,” said Ryan Benton, Interim Chief Executive Officer of Enovix....

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that it has applied for a voluntary delisting of its Class B subordinate voting shares (“Class B Shares”) from the Canadian Securities Exchange (the “CSE”). The delisting from the CSE will not affect the Company’s listing on the...

MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.1 “We are pleased to receive regulatory approval of TAVALISSE in Colombia, providing an important new therapeutic option for adult patients living with chronic immune thrombocytopenia,” said Samira Sakhia, President and CEO of Knight Therapeutics. “This approval represents a meaningful step in addressing...